Success Metrics

Active Trials
11(92%)

Phase Distribution

Ph phase_2
8
67%
Ph phase_1
3
25%
Ph phase_3
1
8%

Phase Distribution

3

Early Stage

8

Mid Stage

1

Late Stage

Phase Distribution12 total trials
Phase 1Safety & dosage
3(25.0%)
Phase 2Efficacy & side effects
8(66.7%)
Phase 3Large-scale testing
1(8.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

11

trials recruiting

Total Trials

12

all time

Status Distribution
Active(12)

Detailed Status

Recruiting7
Active, not recruiting4
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
12
Active
11
Success Rate
N/A
Most Advanced
Phase 3

Trials by Phase

Phase 13 (25.0%)
Phase 28 (66.7%)
Phase 31 (8.3%)

Trials by Status

recruiting758%
not_yet_recruiting18%
active_not_recruiting433%

Recent Activity

11 active trials
Showing 5 of 12
not_yet_recruitingphase_3

JS207 Plus JS007 Versus Toripalimab Plus Bevacizumab as First-Line Treatment for Advanced Liver Cancer

NCT07823348
active_not_recruitingphase_2

JS207Combined With Chemotherapy in First-line Treatment of Advanced NSCLC

NCT06969027
active_not_recruitingphase_2

JS207 Combined With Chemotherapy in Subjects With Stage II-III NSCLC

NCT06944470
recruitingphase_2

JS207 a Bispecific Antibody Against PD1-VEGF in Nasopharyngeal Carcinoma

NCT07690787
active_not_recruitingphase_1

Phase I Study of WJ47156 Monotherarpy and in Combination With Other Therapy in Advanced Solid Tumors

NCT06571422
View all 12 trials

Clinical Trials (12)

Showing 12 of 12 trials
NCT07823348Phase 3

JS207 Plus JS007 Versus Toripalimab Plus Bevacizumab as First-Line Treatment for Advanced Liver Cancer

Not Yet Recruiting
NCT06969027Phase 2

JS207Combined With Chemotherapy in First-line Treatment of Advanced NSCLC

Active Not Recruiting
NCT06944470Phase 2

JS207 Combined With Chemotherapy in Subjects With Stage II-III NSCLC

Active Not Recruiting
NCT07690787Phase 2

JS207 a Bispecific Antibody Against PD1-VEGF in Nasopharyngeal Carcinoma

Recruiting
NCT06571422Phase 1

Phase I Study of WJ47156 Monotherarpy and in Combination With Other Therapy in Advanced Solid Tumors

Active Not Recruiting
NCT06022250Phase 1

The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of JS207 in Patients With Advanced Malignant Tumor

Active Not Recruiting
NCT05582499Phase 2

Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy

Recruiting
NCT06868836Phase 2

Phase II Clinical Study of JS207 (PD-1/VEGF Bispecific Antibody) Combination Therapies in Patients With Driver Gene-Positive, Advanced Non-Small Cell Lung Cancer After Failure of TKI Therapy

Recruiting
NCT07503756Phase 2

JS212 Combination Therapies in Metastatic Colorectal Cancer

Recruiting
NCT07466160Phase 1

A Phase Ib/II Study of 7MW3711 Combined With JS207 in Advanced Solid Tumors

Recruiting
NCT06954467Phase 2

JS207 Combined With JS007 as First-line Treatment for Advanced Hepatocellular Carcinoma

Recruiting
NCT06885385Phase 2

A Phase 2 Study Evaluating the Safety and Efficacy of JS207 With or Without JS015 in Combination With Chemotherapy in Patients With Colorectal Cancer

Recruiting

All 12 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
12